Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”

[1] Caro JJ(2012)Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 Med Decis Making 32 667-677

[2] Briggs AH(2017)Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy Hum Vaccin Immunother 13 2307-2315

[3] Siebert U(2016)Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease Lancet Infect Dis. 16 480-492

[4] Kuntz KM(2016)Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model BMJ Open 6 e010776-831

[5] Castiglia P(2018)Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis 18 830-471

[6] Pradelli L(2014)Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study Lancet Respir Med. 2 464-1027

[7] Castagna S(2017)Health economic analysis of pneumococcal conjugated vaccines for Mexico, under a technical parity scenario Value Health. 20 A932-7213

[8] Freguglia V(2017)Streptococcus pneumoniae serotype 19A: worldwide epidemiology Expert Rev Vaccines. 16 1007-10

[9] Palù G(2015)Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study PLoS One 10 e0120290-78

[10] Esposito S(2018)Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands PLoS One 13 e0192640-94

[1] Caro JJ(2012)Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 Med Decis Making 32 667-677

[2] Briggs AH(2017)Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy Hum Vaccin Immunother 13 2307-2315

[3] Siebert U(2016)Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease Lancet Infect Dis. 16 480-492

[4] Kuntz KM(2016)Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model BMJ Open 6 e010776-831

[5] Castiglia P(2018)Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis 18 830-471

[6] Pradelli L(2014)Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study Lancet Respir Med. 2 464-1027

[7] Castagna S(2017)Health economic analysis of pneumococcal conjugated vaccines for Mexico, under a technical parity scenario Value Health. 20 A932-7213

[8] Freguglia V(2017)Streptococcus pneumoniae serotype 19A: worldwide epidemiology Expert Rev Vaccines. 16 1007-10

[9] Palù G(2015)Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study PLoS One 10 e0120290-78

[10] Esposito S(2018)Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands PLoS One 13 e0192640-94